First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
15 mars 2022 08h00 HE
|
ENA Respiratory
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections ...
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
23 févr. 2022 08h00 HE
|
ENA Respiratory
-- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of...
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
28 sept. 2021 08h00 HE
|
ENA Respiratory
-- ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost...
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
13 juil. 2021 08h00 HE
|
ENA Respiratory
-- First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal...
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
15 juin 2021 08h00 HE
|
ENA Respiratory
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051Company appoints President and Chief Scientific Officer of...